U.S. Physical Therapy: A Strategic Pivot to Hospital Affiliations Reshapes the Model
U.S. Physical Therapy (USPH) is in the midst of a structural transformation that goes beyond typical same-store growth. The company's Q2 2026 results reveal a deliberate pivot toward hospital affiliation agreements, an initiative that generated revenue per visit of $107.59 — a record — and pushed visits per clinic per day to an all-time high of 33.5. This is not a cyclical uptick; it is a business-model evolution that should accelerate into 2027.
The Hospital Affiliation Flywheel
Management spent most of the call detailing the mechanics and runway of its hospital partnerships, most notably the NYU Langone affiliation that now encompasses the former Metro clinics. As Chairman Chris Reading explained in prepared remarks:
once those facilities are transitioned, that creates nothing but upside opportunity with no cost downside based on how these agreements work with our hospital partners.
The economics are straightforward: USPH receives a per-visit fee plus reimbursement for clinical staff, replacing the previous net patient revenue. In Q2, that contributed $5.6 million of revenue, and CFO Jason Curtis clarified the mechanics: “So the $5.6 million comes from 2 components of the agreement with the hospitals. One is a per visit fee... And then additionally, we receive a reimbursement for the licensed clinical staff.” This structure allows USPH to add clinicians without margin risk, as the hospitals absorb the incremental cost. The company has already transitioned 31 clinics this quarter and expects the remaining 39 Metro clinics plus the Gulf Coast partnership to come online during Q3.
The strategic significance extends beyond Metro. Management indicated that the top 30–40 partnerships aggregate 75–80% of earnings and operate in MSA markets with multiple hospital systems, providing a deep pipeline for similar deals. “We feel confident that 2027 is going to look meaningfully different with the next few of these,” Reading added. This echoes prior guidance: in the May 2026 call, he noted, “These hospital opportunities are chunky and make a really nice difference.” The company is also using its enlarged $450 million credit facility (with a $125 million accordion) to fund acquisitions, including a recently announced 12-clinic practice in a new state.
Operating Costs and Headwinds
The pivot comes with near-term friction. Adjusted PT gross margin fell from 21.4% to 19.9% year-over-year, and adjusted operating results per share declined from $0.81 to $0.75. Two factors dominate: an unusually high self-insured healthcare claim level (~$3.2 million year-to-date swing) and the deliberate front-loading of ~50 clinicians hired in advance of the NYU transition. As Reading put it, “We had an opportunity to hire clinicians coming out of school... so we jumped on that,” but it created “short-term cost absorption.” Stated in Q&A: “that cost gets picked up and effectively supplemented by NYU” — Christopher Reading, Chairman and CEO · 2026-08-06 once the clinics roll into the agreement.
The cost pressure shows up in the fundamentals: operating margin contracted to 6.3%, and net income dropped 39% year-over-year to $8 million. However, the company reaffirmed full-year 2026 adjusted EBITDA guidance of $102–106 million, implying a significant back-half ramp. The back-half levers include the full quarterly run-rate benefit of the hospital affiliations (~$1.5–2 million in Q4), continued WelcomeWare (front-office virtualization) rollout, and the Medicare rate increase for 2027, which management expects to add another 1.5% or more.
Outlook and Implications
The market has yet to reward the story—the stock is flat over the last 90 days, though the long-term trend remains deeply positive. The key question is whether the hospital affiliations can scale profitably without diluting the existing model. Management is confident, noting that the original $7.3 million 2027 EBITDA contribution estimate from the NYU deal will likely be exceeded as volume run-rates and cost takeouts (e.g., eliminating back-office billing) embed into the base.
For investors, this is a name-in-transition. The NYU Langone relationship is a proof point, and the pipeline of hospital partnerships could redefine USPH's growth algorithm. But the near-term margin dip—driven by metro clinics ramp costs and self-insured claims—demands patience. As Reading summarized, “We're very confident that the early results are going to position us for a greater number in 2027.” The numbers support that confidence, provided the transition executes on schedule.